News stories about Chemed Corp. (NYSE:CHE) have trended positive on Monday, according to AlphaOne Sentiment. AlphaOne, a subsidiary of Accern, identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chemed Corp. earned a media sentiment score of 0.34 on AlphaOne’s scale. AlphaOne also assigned headlines about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Chemed Corp. (NYSE:CHE) traded up 0.77% during midday trading on Monday, hitting $208.22. 85,537 shares of the company were exchanged. Chemed Corp. has a one year low of $126.54 and a one year high of $216.01. The firm’s 50-day moving average price is $204.48 and its 200-day moving average price is $180.38. The stock has a market capitalization of $3.35 billion, a PE ratio of 30.55 and a beta of 1.17.
Chemed Corp. (NYSE:CHE) last issued its quarterly earnings data on Wednesday, April 26th. The company reported $1.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.04. The business had revenue of $405.90 million for the quarter, compared to analysts’ expectations of $399.75 million. Chemed Corp. had a return on equity of 24.62% and a net margin of 7.14%. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.62 EPS. Equities research analysts anticipate that Chemed Corp. will post $7.95 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 14th. Stockholders of record on Thursday, May 25th were issued a dividend of $0.26 per share. The ex-dividend date was Tuesday, May 23rd. This represents a $1.04 annualized dividend and a dividend yield of 0.50%. Chemed Corp.’s dividend payout ratio (DPR) is 15.25%.
Separately, Zacks Investment Research lowered shares of Chemed Corp. from a “buy” rating to a “hold” rating in a research report on Tuesday, May 2nd.
In other news, insider Kevin J. Mcnamara sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 2nd. The stock was sold at an average price of $205.11, for a total transaction of $820,440.00. Following the sale, the insider now directly owns 148,943 shares of the company’s stock, valued at approximately $30,549,698.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald E. Saunders sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $204.85, for a total value of $81,940.00. Following the sale, the director now directly owns 9,886 shares in the company, valued at $2,025,147.10. The disclosure for this sale can be found here. Insiders have sold a total of 5,400 shares of company stock worth $1,104,850 over the last ninety days. Insiders own 5.32% of the company’s stock.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with our FREE daily email newsletter.